Zacks has a useful updated analysis of IMNP's development of bertilimumab. IMNP just received a decent chunk of funding that will take them well into 2017. ICO, of course, licenses bertilimumab to IMNP and will receive milestone payments if b-mab progresses. Yahoo is not letting me link. Take a look at @ZacksSmallCap on Twitter to find the link.
ICO, if they stick to their schedule, should be filing and IND for their oral Amp B soon ("in the second half of 2015). They also think P1 should be initiated in Q1 2016.
I had missed the publication of "Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature" when it went up back in July. It's published in _Drug Development and Industrial Pharmacy_ Sept, 15.